（1）经科兴生物制药股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实现归属 于母公司所有者的净利润为13,500万元至17,500万元，与上年同期（法定披露数据）相比，将增加 10,352万元至14,352万元，同比增加328.83%至455.89%。 （2）预计归属于母公司所有者的扣除非经常性损益的净利润为5,000万元至7,000万元，与上年同期（法 定披露数据）相比，将增加1,475万元至3,475万元，同比增加41.83%至98.56%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 证券代码：688136 证券简称：科兴制药 公告编号：2026-009 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 除此之外，公司不存在其他影响本次业绩预告内容准确性的重大不确定因素。 五、其他说明事项 以上预告数据仅为初步核算数据，具体准确的财务数据以公司正式披露的经审计后的 ...

Group 1 - Guangdong Mingzhu expects a net profit increase of 2908.49%-3577.04% year-on-year for 2025 [1] - Sainuo Medical anticipates a net profit growth of 2767%-3233% year-on-year for 2025 [1] - Lingdian Electric Control forecasts a net profit rise of 640.16%-804.64% year-on-year for 2025 [1] - Bojie Co. predicts a net profit increase of 484.16%-618.97% year-on-year for 2025 [1] - Kexing Pharmaceutical expects a net profit growth of 328.83%-455.89% year-on-year for 2025 [1] - Xiangcai Co. anticipates a net profit increase of 266.41%-403.81% year-on-year for 2025 [1] - Xinyi Sheng forecasts a net profit rise of 231.24%-248.86% year-on-year for 2025 [1] - Tongzhou Electronics predicts a net profit increase of 151.40%-230.42% year-on-year for 2025 [1] - Zhaofeng Co. expects a net profit growth of 136.26%-164.89% year-on-year for 2025 [1] - Kaige Precision Machinery anticipates a net profit increase of 133.99%-193.55% year-on-year for 2025 [1] - Sankeshu forecasts a net profit rise of 128.96%-189.21% year-on-year for 2025 [1] - Huazi Industrial expects a net profit growth of 128.00%-167.00% year-on-year for 2025 [1] - Zhite New Materials anticipates a net profit increase of 117.11%-171.39% year-on-year for 2025 [1] - Ecovacs expects a net profit growth of 110.90%-123.30% year-on-year for 2025 [1] - Jingquan Hua forecasts a net profit increase of 109.32%-140.72% year-on-year for 2025 [1] - Guoxuan High-Tech anticipates a net profit rise of 107.16%-148.59% year-on-year for 2025 [1] - Changjiang Securities expects a net profit growth of 101.37% year-on-year for 2025 [1] - Shanwaishan forecasts a net profit increase of 98%-125% year-on-year for 2025 [1] - Zhongji Xuchuang anticipates a net profit rise of 89.50%-128.17% year-on-year for 2025 [1] - Huachuang Yuxin expects a net profit growth of 86%-175% year-on-year for 2025 [1] - Kori Technology forecasts a net profit increase of 68.61%-115.25% year-on-year for 2025 [1] - Western Gold anticipates a net profit rise of 67.58%-93.21% year-on-year for 2025 [1] - Shandong Gold expects a net profit growth of 56%-66% year-on-year for 2025 [1] - Huaxi Biological anticipates a net profit increase of 54.93%-83.63% year-on-year for 2025 [1] - Nairui Radar expects a net profit growth of approximately 54.16% year-on-year for 2025 [1] - Lingyun Optical anticipates a net profit rise of approximately 50.75% year-on-year for 2025 [1] - Zhongjin Company expects a net profit increase of 50%-85% year-on-year for 2025 [1] - Dongwu Securities forecasts a net profit growth of 45%-55% year-on-year for 2025 [1] - Longping High-Tech anticipates a net profit increase of 14.17%-66.86% year-on-year for 2025 [1] Group 2 - Jiangfeng Electronics expects a net profit increase of 7.5%-27.5% year-on-year for 2025 [2]

Group 1: Earnings Forecasts - Han's Laser expects a net profit of 1.85 billion to 2.15 billion yuan for 2025, marking a turnaround from losses in the previous year [9] - Zhongji Xuchuang anticipates a net profit increase of 89.50% to 128.17% for 2025, projecting profits between 9.8 billion to 11.8 billion yuan [2] - Perfect World forecasts a net profit of 720 million to 760 million yuan for 2025, also reversing previous losses [25] - Yihua Lifestyle expects a net profit of 8 billion to 10 billion yuan for 2025, compared to a loss of 1.696 billion yuan in the previous year [21] - Guizhou Mingzhu anticipates a staggering net profit increase of 2908.49% to 3577.04% for 2025, projecting profits between 166 million to 203 million yuan [25] - Kexing Pharmaceutical expects a net profit increase of 328.83% to 455.89% for 2025, projecting profits between 135 million to 175 million yuan [28] Group 2: Capital Raising and Investments - Newray plans to raise no more than 1.316 billion yuan through a private placement for high-performance CNC blade industrial park projects [3] - Liyang Chip intends to raise up to 970 million yuan for integrated circuit testing projects and other initiatives [4] - Kid King plans to invest 3.3 million yuan to establish a joint venture focused on online business model innovation for family consumption [6] Group 3: Industry Developments - Tianqi Lithium's subsidiary has produced its first batch of chemical-grade lithium concentrate as part of its expansion project [5] - Yihua Lithium's subsidiary has signed a framework agreement with Indonesian state-owned enterprises to collaborate on the entire supply chain for electric vehicle batteries [7] - Longyuan Power expects a net profit increase of 51% to 73% for 2025, driven by improved profitability in its core thermal power business and expansion in renewable energy [18]

证券日报网讯 1月30日，科兴制药发布公告称，公司预计 2025 年年度实现归属于母公司所有者的净利 润为 13，500 万元至 17，500万元，与上年同期（法定披露数据）相比，将增加 10，352 万元至 14， 352 万元，同比增加 328.83%至 455.89%。 （文章来源：证券日报） ...

Core Viewpoint - The company, Sinovac Biotech (688136.SH), expects a significant increase in net profit for the year 2025, driven by strong growth in overseas markets and a substantial rise in operating income [1] Financial Performance - The estimated net profit attributable to the parent company for 2025 is projected to be between 135 million and 175 million yuan, representing an increase of 103.52 million to 143.52 million yuan compared to the previous year, which is a year-on-year increase of 328.83% to 455.89% [1] - The estimated net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 50 million and 70 million yuan, reflecting an increase of 14.75 million to 34.75 million yuan compared to the previous year, translating to a year-on-year increase of 41.83% to 98.56% [1] Market Expansion - The company is actively expanding into overseas markets, which has led to strong growth in overseas revenue, contributing to the continuous increase in operating income [1] - The significant changes in non-recurring gains and losses during the reporting period are mainly due to the fair value changes of private equity funds held by the company and the disposal of subsidiaries [1]

北京商报讯（记者 王寅浩 宋雨盈）1月30日，科兴制药发布2025年业绩预告，预计2025年实现归属于母 公司所有者的净利润为1.35亿—1.75亿元，同比增加328.83%—455.89%。预计归属于母公司所有者的扣 除非经常性损益的净利润为5000万—7000万元，同比增加41.83%—98.56%。 根据公告，2025年，科兴制药积极开拓海外市场，实现了海外收入增长，推动营收持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。 ...

2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收入持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。报告期内非经常性 损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子公司所致。 格隆汇1月30日丨科兴制药(688136.SH)公布，经公司财务部门初步测算，预计2025年年度实现归属于母 公司所有者的净利润为13,500万元至17,500万元，与上年同期（法定披露数据）相比，将增加10,352万 元至14,352万元，同比增加328.83%至455.89%。预计归属于母公司所有者的扣除非经常性损益的净利润 为5,000万元至7,000万元，与上年同期（法定披露数据）相比，将增加1,475万元至3,475万元，同比增加 41.83%至98.56%。 ...

每经AI快讯，1月30日，科兴制药(688136.SH)公告称，预计2025年归属于上市公司股东的净利润为1.35 亿元至1.75亿元，同比增长328.83%-455.89%。业绩变动主要原因系公司积极开拓海外市场，实现海外 收入强劲增长，推动营业收入持续增长，带动净利润大幅上升。 （文章来源：每日经济新闻） ...

每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 每经AI快讯，科兴制药1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为1.35亿元~1.75亿元，与上年同期相比，将增加约1.04亿元至1.44亿元，同比增加328.83%~455.89%。 业绩变动主要原因是，2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收 入持续增长，归属于母公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提 升。报告期内非经常性损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子 公司所致。 （记者 曾健辉） ...

证券代码：688136 证券简称：科兴制药 公告编号：2026-009 科兴生物制药股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 （1）经科兴生物制药股份有限公司（以下简称"公司"）财务部门初步测 算，预计 2025 年年度实现归属于母公司所有者的净利润为 13,500 万元至 17,500 万元，与上年同期（法定披露数据）相比，将增加 10,352 万元至 14,352 万元， 同比增加 328.83%至 455.89%。 （2）预计归属于母公司所有者的扣除非经常性损益的净利润为 5,000 万元 至 7,000 万元，与上年同期（法定披露数据）相比，将增加 1,475 万元至 3,475 万元，同比增加 41.83%至 98.56%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总额：5,690.26 万元。归属于母公司所有者的净利润：3,148.09 万元。归属于母公司所有者的扣除非经常性损益的净 ...